Innoviva Number of Employees 2010-2024 | INVA

Innoviva number of employees from 2010 to 2024. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Innoviva Annual Employee Count
2023 112
2022 101
2021 5
2020 5
2019 6
2018 6
2017 12
2016 14
2015 13
2014 10
2013 241
2012 226
2011 222
2010 193
2009 194
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.131B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $827.866B 67.16
Johnson & Johnson (JNJ) United States $384.448B 15.98
Novo Nordisk (NVO) Denmark $375.786B 25.45
AbbVie (ABBV) United States $354.625B 19.85
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Merck (MRK) United States $221.798B 11.48
Novartis AG (NVS) Switzerland $219.342B 13.74
Pfizer (PFE) United States $146.775B 8.33
Sanofi (SNY) $137.374B 13.01
Bayer (BAYRY) Germany $22.556B 3.61